Monitoring coronary artery plaque progression in people with type 2 diabetes.
Official title: Evaluating Atherosclerotic Disease Progression in High-Risk Patients With Diabetes Mellitus
Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT07237685 · Data updated 2026-11-12
This project will follow adults with type 2 diabetes who already had a coronary CT angiography to see how plaque in their heart arteries changes over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 2 sites (Amsterdam and 1 other locations) |
| Status | Recruiting |
| Started | June 6, 2025 |
| Main results expected | October 1, 2026 |
| Study ends | October 1, 2036 |
| Registry record updated | November 20, 2025 |
| Trial ID | NCT07237685 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 with diagnosed type 2 diabetes on glucose-lowering treatment who have a prior CCTA performed 2–5 years ago with at least two of three coronary vessels imaged at sufficient quality.
✕Probably not a fit
Patients with severe renal dysfunction, known contrast allergy, unstable medical conditions, unacceptable image quality, or a baseline CCTA performed outside the 2- to 5-year window are unlikely to be eligible or derive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project follows adults with type 2 diabetes who previously underwent coronary CT angiography (CCTA) to track changes in coronary plaque over time. Prior CCTA images that meet quality criteria will be re-analyzed and compared with repeat imaging and routine clinical data collected during follow-up. The study records plaque burden, composition, and progression alongside clinical events and treatments, focusing on participants receiving glucose-lowering therapy. Results aim to improve understanding of how atherosclerotic disease advances in people with diabetes and to identify imaging features that predict future heart problems.
Why it matters
Potential benefit: If successful, this work could help doctors identify which patients with type 2 diabetes are at higher risk for worsening coronary artery disease so they can receive earlier or more intensive prevention.
How similar studies have gone: Previous studies using serial coronary CT angiography have demonstrated the ability to detect plaque progression and predict cardiovascular events, but large-scale data specifically focused on progression in treated type 2 diabetes patients remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 years * Previous completion of CCTA scan for CAD assessment * Diagnosed with Type 2 Diabetes and currently receiving glucose lowering treatment * Sufficient image quality of the CCTA scan (at least 2/3 vessels of sufficient quality for assessment). Exclusion Criteria: * Inability to provide written informed consent * Presence of an unstable condition * Ingeligibility for CCTA acquisition due to severe renal dysfunction (eGFR ≤ 30 mL/min/1.73m²) or known hypersensitivity or contraindication to CT contrast agents * Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator * inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study * Baseline (routine care) CCTA performed \< 2 years or \> 5 years before inclusion
Where it's running
-
Cardiology Centers of the Netherlands
Amsterdam, Netherlands Recruiting -
Amsterdam University Medical Centers
Amsterdam, Netherlands Not yet recruiting
Study contacts
- Study coordinator: Willem R van de Vijver, MD
- Email: w.r.vandevijver@amsterdamumc.nl
- Phone: +31205662402
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acute Blood Flow Restriction Walking in Type 2 Diabetes
This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.
-
TAVI and PCI vs SAVR and CABG in low- and intermediate-risk patients with severe aortic stenosis and CAD
This observational study compares TAVI plus PCI to SAVR plus CABG for patients who have both severe aortic stenosis and coronary artery disease.
-
Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin
This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.
-
Differentiating heart disease in autoimmune vs. type 2 diabetes
This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.
-
Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses
This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.
-
Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar
This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.